Jun 16
While tech evangelists often tout artificial intelligence (AI) as healthcare’s silver bullet, the reality in clinical trials is more complex. Adoption has been cautious, shaped as much by concerns around trust and governance as by technical hurdles. Still, beneath the surface, methodical innovation is gaining momentum. AI is beginning to reshape how trials are designed, executed, and scaled, offering new ways to reduce patient burden, improve data quality, and accelerate development.
Read the full article by Rob DiCicco from Drug Discovery News here.
Related Blog Posts
Scrip Asks… What Does 2026 Hold For Biopharma? Part 4: R&D Innovation
Enthusiastic predictions from industry leaders for ongoing progress in obesity, oncology, immunology, neuroscience and more were supported by optimism for the potential of AI and other technological advances to enable breakthroughs in processes as well as pipelines. Read the full article featuring Rob DiCicco from Citeline here.
Digital Protocols Are At An Inflection Point: A Conversation With Novartis And TransCelerate Leaders
Interest in digital approaches to clinical protocols has grown steadily as sponsors, solution providers, sites, and regulators explore ways to make study planning and execution more efficient. Read the full article featuring Rob DiCicco from Clinical Leader here.
Scrip Asks… What Does 2026 Hold For Biopharma? Part 2: Competitive Dynamics – A Landscape Reshaped
Regulatory divergence across major markets is creating strategic complexity that compounds geographic competitive pressures. Read the full article featuring Allison Cuff Shimooka from Citeline here.